gd2, psma and cd276 car-t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 18, 2020 (NCT04637503)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- CD276 antigenImmunity, passive
CD276 immunity, passive
- Glutamate carboxypeptidase IIImmunity, passive
FOLH1 immunity, passive
- Disialoganglioside GD2Immunity, passive
Disialoganglioside GD2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04637503 | Phase 1/Phase 2 (Phase 2) | Nov 18, 2020 | Shenzhen Geno-Immune Medical Institute, Shenzhen University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shenzhen Geno-Immune Medical Institute | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Shenzhen University | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1